Evidence map›Paper›PMID 19017280›Full record

ArticleOral diseases2009

Effect of HAART on salivary gland function in the Women's Interagency HIV Study (WIHS).

M Navazesh, R Mulligan, R Karim, W J Mack, S Ram, H Seirawan, J Greenspan, D Greenspan, J Phelan, M Alves and 1 more

Open access · greenAbstract readComparative StudyMulticenter Study
In one paragraph

Article in Oral diseases, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 55 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Dental Health Status of HIV-Positive Patients and Related Variables in Southeast Iran.International journal of high risk behaviors & addiction · 2016
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Effects of long-term use of HAART on oral health status of HIV-infected subjects.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

M NavazeshUSC School of Dentistry, Los Angeles, CA 90089-0641, USA. navazesh@usc.edu
R Mulligan
R Karim
W J Mack
S Ram
H Seirawan
J Greenspan
D Greenspan
J Phelan
M Alves
Oral Substudy of the Women's Interagency HIV Study Collaborative Study Group*
Southern California University for Professional Studies · USUniversity of California, San Francisco · USNational Medical Research Center of Dentistry and Maxillofacial Surgery · RUUniversity of Illinois Chicago · USUniversity of Southern California · US

Funding

Women's Interagency HIV Study (WIHS-V)U01AI035004 · NIAID · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI ANASTOS, KATHRYN M., SHARMA, ANJALI · 1993 to 2018
$65.7M
WOMEN'S INTERAGENCY HIV STUDY ORGANIZATION, MANAGEMENT AND COMMUNICATIONSU01AI034989 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AOUIZERAT, BRADLEY E, GREENBLATT, RUTH MARTHA · 1993 to 2018
$65.6M
Women's Interagency HIV Study (WIHS) IIIU01AI031834 · NIAID · SUNY DOWNSTATE MEDICAL CENTER · PI GUSTAFSON, DEBORAH R., MINKOFF, HOWARD · 1998 to 2018
$53.5M
WOMEN'S INTERAGENCY HIV STUDY (WIHS) ORGANIZATION AND MANAGEMENTU01AI034994 · NIAID · GEORGETOWN UNIVERSITY · PI KASSAYE, SEBLE G · 1993 to 2018
$52.0M
Women's Interagency HIV Study (WIHS) IV, Chicago ConsortiumU01AI034993 · NIAID · HEKTOEN INSTITUTE FOR MEDICAL RESEARCH · PI COHEN, MARDGE H, FRENCH, AUDREY · 1994 to 2018
$51.0M
WOMENS INTERAGENCY HIV STUDY (WIHS)U01HD032632 · NICHD · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MILAM, JOEL E · 1994 to 2012
$42.0M
WIHS DATA MANAGEMENT AND ANALYSIS CENTER(WDMAC)U01AI042590 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GANGE, STEPHEN J, GOLUB, ELIZABETH T · 1998 to 2018
$38.4M
NIAID NIH HHS U01 AI031834NIAID NIH HHS U01 AI034989NIAID NIH HHS U01 AI034993NIAID NIH HHS U01 AI034994NIAID NIH HHS U01 AI035004NIAID NIH HHS U01 AI042590NIAID NIH HHS U01-AI-31834NIAID NIH HHS U01-AI-34989NIAID NIH HHS U01-AI-34993NIAID NIH HHS U01-AI-34994NIAID NIH HHS U01-AI-35004NIAID NIH HHS U01-AI-42590NICHD NIH HHS U01 HD032632NICHD NIH HHS U01-HD-32632
6 · The paper itself

Abstract

objectiveTo determine the impact of highly active antiretroviral therapy (HAART) on salivary gland function in human immunodeficiency virus (HIV) positive women from the Women's Interagency HIV Study (WIHS).

designLongitudinal cohort study. SUBJECTS AND

methodsA total of 668 HIV positive women from the WIHS cohort with an initial and at least one follow-up oral sub-study visit contributed 5358 visits. Salivary gland function was assessed based on a dry mouth questionnaire, whole unstimulated and stimulated salivary flow rates, salivary gland enlargement or tenderness and lack of saliva on palpation of the major salivary glands.

main outcome measuresChanges in unstimulated and stimulated flow rates at any given visit from that of the immediate prior visit (continuous variables). The development of self-reported dry mouth (present/absent), enlargement or tenderness of salivary glands (present/absent), and absence of secretion on palpation of the salivary glands were binary outcomes (yes/no).

resultsProtease Inhibitor (PI) based HAART was a significant risk factor for developing decreased unstimulated (P = 0.01) and stimulated (P = 0.0004) salivary flow rates as well as salivary gland enlargement (P = 0.006) as compared with non-PI based HAART.

conclusionsPI-based HAART therapy is a significant risk factor for developing reduced salivary flow rates and salivary gland enlargement in HIV positive patients.

Indexed as

Antiretroviral Therapy, Highly ActiveAdolescentAdultAgedAnti-HIV AgentsCD4 Lymphocyte CountCohort StudiesFemaleFollow-Up StudiesHIVHIV Protease InhibitorsHIV Reverse TranscriptaseHIV SeropositivityHumansLongitudinal StudiesMiddle AgedAnti-HIV AgentsHIV Protease InhibitorsHIV Reverse TranscriptaseReverse Transcriptase InhibitorsRNA, Viral

Identifiers

PMID19017280
PMCPMC2644059
OpenAlexW1967984274

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.